BioStem Technologies filed a Form 10 registration statement with the U.S. Securities and Exchange Commission to register its shares of common stock, reaffirming its strategic decision to pursue a listing on the Nasdaq Stock Market. This move aims to enhance credibility, expand access to capital, improve market visibility and liquidity, and reinforce the ability to attract talent. The company believes completing the registration process will position BioStem to execute its long-term growth strategy and create sustainable value for shareholders.

Jason Matuszewski, Chief Executive Officer and Chairman of BioStem Technologies, stated that the filing advances the path toward a Nasdaq uplisting and reflects a commitment to operating as an SEC reporting company. He emphasized that this is the right step as the company continues to strengthen its position in the public markets.

The Registration Statement has not been declared effective by the SEC and will become effective following the conclusion of the SEC’s review. An effective Registration Statement is a required step of the Nasdaq uplisting process. Until BioStem is able to uplist to Nasdaq, its common stock will continue to trade on the OTC market under the ticker symbol "BSEM".

About BioStem Technologies

BioStem Technologies is a publicly traded biomedical innovator focused on developing, manufacturing, and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages proprietary BioRetain®, CryoTek® and SteriTek® processing technologies to optimize tissue preservation.

Key Details

The company's quality management system and standard operating procedures are accredited by the American Association of Tissue Banks and are in compliance with current Good Tissue Practices and current Good Manufacturing Practices. BioStem’s portfolio includes the Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.

BioStem Technologies Inc. (OTC:BSEM), a regenerative medicine company focused on perinatal tissue allograft products, announced that its management will present at the Planet MicroCap Las Vegas 2026 Conference. The presentation is scheduled for Wednesday, June 17, 2026, at 3:00 PM ET. This event provides an opportunity for the company to showcase its advancements in regenerative medicine to a broader audience of investors and industry participants.

Presentation Details

The presentation will be accessible to interested parties via live and archived webcasts. Investors can view the session by visiting the "investors" section of the BioStem Technologies website. The webcast availability ensures that stakeholders who cannot attend the conference in person can still access the information shared by the company's management.

Company Overview

BioStem Technologies is a publicly traded biomedical innovator specializing in the development, manufacturing, and commercialization of advanced allograft solutions derived from perinatal tissue. The company utilizes proprietary technologies, including BioRetain®, CryoTek®, and SteriTek®, to optimize the preservation of tissue properties for clinical use. Its products are employed by clinicians across various medical specialties.

Quality and Compliance

The company's quality management system and standard operating procedures are accredited by the American Association of Tissue Banks (AATB). These systems comply with current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP). BioStem's portfolio includes brands such as Neox®, Clarix®, VENDAJE®, and American Amnion™.